Vaccination status among COVID-19 patients and duration of Polymerase Chain Reaction test positivity: evaluation of immunization schedule and type of vaccine
Keywords:
COVID-19; vaccine; booster; molecular buffer; PCR positivityAbstract
Background. The introduction of the vaccine against SARS-CoV-2 has represented a cornerstone in the containment of the pandemic. Our aim was to assess the vaccination schedules in relation to the infection free interval and to the duration of positivity in case of infection.
Study design. This study involves the SARS-CoV-2 infected people managed by the Local Health Authority ASL 1 Abruzzo. The data collected included: vaccine administration date, vaccine type, information on the Polymerase Chain Reaction test positivity, and demographic variables, such as age and sex.
Methods. The duration of Polymerase Chain Reaction test positivity was assessed in relation to the vaccination status, the vaccine type and the time interval between the last vaccination dose and the first nasopharyngeal positive swab over the considered period. Results. The infection duration (DAYS) was significantly shorter in subjects vaccinated with a booster dose than unvaccinated subjects (12.8 vs 14.6; p<0.0001) and subjects vaccinated with the primary series only (12.8 vs 14.1; p<0.0001). Duration of PCR positivity was shorter with heterologous immunisation than with other vaccination schedules (p=0.0317).
Conclusions. This study highlights, in a large cohort of patients, the association between vaccination schedule and the response to infection.
References
1. COVID-19: cause, disturbi, accertamento, possibili cure, prevenzione - ISSalute. Available from: https://www.issalute.it/index.php/la-salute-dalla-a-alla-z-menu/c/covid-19?highlight=WzFd [Last accessed: 2024 Jan 23].
2. Acito M, Rondini T, Gargano G, Moretti M, Villarini M, Villarini A. How the COVID-19 pandemic has affected eating habits and physical activity in breast cancer survivors: the DianaWeb study. J Cancer Surviv. 2023 Aug;17(4):974-985. doi: 10.1007/s11764-022-01294-w. Epub 2022 Dec 13. PMID: 36512160; PMCID: PMC9745269.
3. Acito M, Natalucci V, Rondini T, Gargano G, Emili R, Moretti M, et al. The DianaWeb cohort during the first COVID19 lockdown: changes in eating behaviour in women with breast cancer. Acta Biomed. 2023 Aug 30;94(S3):e2023135.
doi: 10.23750/abm.v94iS3.14285. PMID: 37695191.
4. Harrison, Principi di Medicina Interna, 20a edizione -2021. Carosi G, Cauda R, Pession A, Antonelli G. La pandemia di COVID-19 in Italia. CEA-Casa Editrice Ambrosiana; Rev 2021.
5. Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview (published correction appears in Diabetes Metab Syndr. 2022 May;16(5):102504). Diabetes Metab Syndr. 2021;15(3):869-875. doi:10.1016/j.dsx.2021.04.
6. Rapporto ISS COVID-19 n. 11/2020 Rev.2. Raccomandazioni ad interim per il corretto prelievo, conservazione e analisi sul tampone rino/orofaringeo per la diagnosi di COVID-19.
7. Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022;399(10326):757-768. doi:10.1016/S01406736(21)02346-1.
8. Bollettino sorveglianza integrata Covid-19. Aggiornamento Nazionale relativo al periodo 08/01/2024 – 14/01/2024 dei dati della Sorveglianza Integrata COVID-19. Available from: https://www.epicentro.iss.it/coronavirus/bollettino/ Bollettino-sorveglianza-integrata-COVID-19_10-gennaio2024.pdf [Last accessed: 2024 Jan 23].
9. De Luca A, Flammini G, Vittorini P, Muselli M, Mastrantonio R, Cipollone C, et al. . Impact of the healthcare reorganization of the Local Health Authority services in Rieti (Italy) during the SARS-CoV-2 pandemic. Ann Ig. 2023 Jul-Aug;35(4):441-453. doi: 10.7416/ai.2023.2560. Epub 2023 Feb 20.
10. Monitoraggio COVID Provincia dell’Aquila. Available from: www.opendatacovid.it/covid [Last accessed: 2024 Jan 23].
11. Bollettino sorveglianza integrata Covid-19. Aggiornamento Nazionale relativo al periodo 11/12/2023 – 17/12/2023 dei dati della Sorveglianza Integrata COVID-19. Available from: https://www.epicentro.iss.it/coronavirus/bollettino/ Bollettino-sorveglianza-integrata-COVID-19_20-dicembre2023.pdf [Last accessed: 2024 Jan 23].
12. Istituto Superiore di Sanità (ISS). Available from: www.iss. it/web/guest/vaccini-covid-19 [Last accessed: 2022 February 20].
13. Ministero della Salute. Available from: www.salute.gov.it/ [Last accessed: 2024 Jan 23].
14. Impatto della vaccinazione COVID-19 sul rischio di infezione da SARS-CoV-2 e successivo ricovero e decesso in Italia. Ministero della Salute. Available from: https://www. iss.it/-/impatto-della-vaccinazione-covid-19-sul-rischio-diinfezione-da-sars-cov-2-e-successivo-ricovero-e-decessoin-italia [Last accessed: 2024 Jan 23].
15. Ministero della salute. Report Vaccini Anti-COVID-19. Available from: https://www.governo.it/it/cscovid19/reportvaccini/ [Last accessed: 2024 Jan 23].
16. Bollettino sorveglianza integrata Covid-19. Report Esteso ISS. Covid-19: Sorveglianza, impatto delle infezioni ed efficacia vaccinale. Aggiornamento Nazionale 11 Maggio 2022 ore 12:00. Data pubblicazione 13.05.2022.
17. World Health Organization (WHO). Update on omicron. Available from: https://www.who.int/news/item/26-112021-classification-of-omicron-(b.1.1.529)-sars-cov-2variant-of-concern [Last accessed: 2024 Jan 23].
18. European Centre for Disease Prevention and Control (ECDC). Epidemiological UpdateOmicron Variant of Concern. Available from: https://www.ecdc.europa.eu/en/ news-events/epidemiological-update-omicron-data-30november-2021 [Last accessed: 2024 Jan 23].
19. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J Med Virol. 2022;94(7):2969-2976. doi:10.1002/jmv.
20. Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O,
Cohen C, et al. Third BNT162b2 Vaccination Neutraliza-
tion of SARS-CoV-2 Omicron Infection. N Engl J Med. 2022;386(5):492-494. doi:10.1056/NEJMc2119358. Epub 2021 Dec 29.
21. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022;327(7):639-651. doi:10.1001/jama.2022.0470.
22. Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, GolanCohen, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. medRxiv [Preprint]. 2021 Aug 5:2021.08.03.21261496. Update in: BMJ. 2021 Nov 24;375:e067873. doi:10.1101/2021.08.03 .21261496.
23. Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. JAMA Intern Med. 2022;182(2):179-184. doi:10.1001/jamainternmed.2021.7382.
24. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. N Engl J Med. 2022 Apr 7;386(14):1377-1380. doi: 10.1056/ NEJMc2202542. Epub 2022 Mar 16.
25. Ronchini C, Gandini S, Pasqualato S, Mazzarella L, Facciotti S, Mapelli M, et al. Lower probability and shorter duration of infections after COVID-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs. PLoS One. 2022 Jan
31;17(1): e0263014. doi:10.1371/journal.pone.0263014
26. Blomberg BB, Frasca D. Quantity, not quality, of antibody response decreased in the elderly. J Clin Invest. 2011;121(8):2981-2983. doi:10.1172/JCI58406.
27. Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020;145(5):1309-1321. doi:10.1016/j. jaci.2020.03.017.
28. Pera A, Campos C, López N, Hassouneh F, Alonso C, Tarazona R, et al. Immunosenescence: Implications for response to infection and vaccination in older people. Maturitas. 2015;82(1):50-55. doi:10.1016/j.maturitas.2015.05.004. Epub 2015 May 18.
29. Frasca D, Blomberg BB. Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination. Immun Ageing. 2020 Nov 19;17(1):37. doi:10.1186/s12979-020-00210-z.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Paola Guerriero, Claudia Cipollone, Roberta Martinelli, Federica Caputo, Maurizio Cervellini, Leondino Mammarella, Mario Muselli, Riccardo Mastrantonio, Giada Mastrangeli, Leila Fabiani (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.